Clinical Trials on Hepatitis C Chronic in New Zealand

Total 4467 results

Hoffmann-La Roche

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

Hepatitis B, Chronic

Australia, New Zealand, Singapore, Thailand, Taiwan, China, Bulgaria, Hong Kong
Gilead Sciences

Terminated

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Chronic Hepatitis B

New Zealand, Korea, Republic of, Hong Kong, United States, Canada, Australia, Italy, India
Gilead Sciences

Completed

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection (ASTRAL-3)

Hepatitis C Virus Infection

United States, France, New Zealand, Canada, Germany, Puerto Rico, United Kingdom, Australia, Italy
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Chronic Hepatitis B

United States, Hong Kong, Korea, Republic of, Taiwan, United Kingdom, Canada, New Zealand, Italy
Assembly Biosciences

Terminated

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

China, Korea, Republic of, United States, United Kingdom, Australia, Canada, Hong Kong, Taiwan, New Zealand
Gilead Sciences

Completed

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Chronic Hepatitis B

Taiwan, France, Germany, Hong Kong, United States, Canada, New Zealand, Australia, Singapore, Poland, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (ESRD)

Hepatitis C Virus Infection

United States, Taiwan, Belgium, Germany, Italy
Hoffmann-La Roche

Completed

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

Hepatitis B, Chronic

Thailand, Taiwan, United Kingdom, Hong Kong, Netherlands, New Zealand, Bulgaria, Italy
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

HCV Infection

New Zealand, United States, Puerto Rico
Kirby Institute

Completed

Treatment of Recently Acquired Hepatitis C Virus Infection (ATAHC-II)

Acute Hepatitis C

Australia
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Hepatitis C Infection

United States, France
Bristol-Myers Squibb

Completed

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Hepatitis C Virus Infection

Australia, France, Germany, Korea, Republic of, Sweden, Taiwan, United Kingdom, United States, Canada, Mexico, Austria, Italy, Spain, Denmark, Argentina, Poland, Ireland, Greece, New Zealand
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Hepatitis C

United States, Australia, New Zealand, Puerto Rico
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Gilead Sciences

Terminated

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Hepatitis C Virus Infection

United States, Canada, Puerto Rico
Arrowhead Pharmaceuticals

Terminated

Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (MONARCH)

Hepatitis B | Hepatitis D

Korea, Republic of, Australia, Thailand, Taiwan, New Zealand, Bulgaria, China, Moldova, Republic of
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Novartis Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

Chronic Hepatitis B

United States, Australia, Canada, China, Czechia, France, Germany, Hong Kong, India, Israel, Italy, Korea, Republic of, New Zealand, Poland, Puerto Rico, Singapore, Spain, Taiwan, Thailand, Turkey, United Kingdom
Bristol-Myers Squibb

Completed

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients (HEPCAT)

Hepatitis C Virus

Australia, Sweden, United States, Canada, France, Germany, Denmark, Mexico, Italy, Puerto Rico, Egypt
Raymond Chung
Johns Hopkins University; University of Pennsylvania; Northwestern University; ... and other collaborators

Completed

Multi-center Study to Transplant Hepatitis-C Infected Kidneys (MYTHIC)

Hepatitis C | Renal Failure Chronic

United States
Benedetta Mattioli

Unknown

The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals (PROBE-C)

HIV | Acute Hepatitis C

Germany
Institute of Liver and Biliary Sciences, India

Withdrawn

Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients

Chronic Hepatitis B

India
Weill Medical College of Cornell University
Schering-Plough

Terminated

Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin

HIV Infections | Anemia | Neutropenia | Hepatitis C Virus

United States
Northwell Health

Completed

Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound

Alcoholism | Cirrhosis | Hepatitis c

United States
Bristol-Myers Squibb

Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (HEPCAT)

Hepatitis C Virus

Australia, France, Mexico, United States, Canada, Germany, Denmark, Italy, Puerto Rico, Sweden, Argentina
Institute of Liver and Biliary Sciences, India

Recruiting

TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.

Non-cirrhotic, Chronic Hepatitis B

India
Bristol-Myers Squibb

Completed

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Hepatitis C Virus

Australia, United States, Canada, France, Denmark, Italy
Vir Biotechnology, Inc.

Recruiting

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (MARCH)

Hepatitis B, Chronic

Hong Kong, Korea, Republic of, Malaysia, New Zealand, Taiwan, United Kingdom, Romania, United States, Moldova, Republic of, Canada, Germany, Ukraine
Research Foundation for Mental Hygiene, Inc.
Icahn School of Medicine at Mount Sinai; Weill Medical College of Cornell University

Terminated

Armodafinil for Patients Starting Hepatitis C Virus Treatment

Hepatitis C

United States
Beth Israel Deaconess Medical Center
Schering-Plough

Completed

Study of Long-term Peg Intron vs. Colchicine in Non-responders. (COPILOT)

Cirrhosis | Hepatitis C Virus | Advanced Fibrosis

United States
Maimonides Medical Center

Withdrawn

Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients

Chronic Hepatitis B

United States
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Hepatitis C | Cirrhosis | Portal Hypertension | With or Without Liver Decompensation

United States, Spain, New Zealand, Australia, France
Gilead Sciences

Recruiting

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

United States, Taiwan, Korea, Republic of, India, New Zealand, Belgium, Canada, Italy, Romania, Russian Federation, Hong Kong
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis (VALOR-HCV)

Hepatitis C Virus Infection

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
Rockefeller University
NYU Langone Health

Recruiting

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

Hepatitis b Virus

United States
Gilead Sciences

Completed

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Hepatitis C Virus Infection

United States, France
Gilead Sciences

Completed

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Hepatitis C Virus

United States, Puerto Rico
Gilead Sciences

Completed

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

HBeAg-negative Chronic Hepatitis B

Hong Kong, United States, United Kingdom, Canada, Australia, Spain, Taiwan, India, Japan, Poland, Romania, Russian Federation, Korea, Republic of, Italy, New Zealand, France, Turkey
Biotest Pharmaceuticals Corporation

Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Liver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | Viruses

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

HIV-1 and Hepatitis C Co-Infection

United States
Rockefeller University
National Institute on Drug Abuse (NIDA)

Completed

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

Hepatitis C

United States
Gilead Sciences

Completed

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

Chronic Hepatitis B

United States
Gilead Sciences

Completed

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

Chronic Hepatitis B

France, Canada, Spain, Germany, Italy, United States, New Zealand, Australia, Czech Republic, Bulgaria, Turkey, Poland, Greece, Netherlands, United Kingdom
Gilead Sciences

Completed

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

Chronic Hepatitis B

Australia, France, Canada, Spain, Turkey, Italy, United States, Greece, Germany, New Zealand, Czech Republic, Bulgaria, Poland, United Kingdom, Netherlands
AbbVie

Completed

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, France, Germany, Poland, Puerto Rico, Russian Federation, Spain, United Kingdom
AbbVie

Completed

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Hepatitis C

United States, Australia, Belgium, Canada, Germany, New Zealand, Puerto Rico, United Kingdom
Hoffmann-La Roche

Completed

A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B

Hepatitis B, Chronic

Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, France, Thailand, Russian Federation, Australia, Italy

Clinical Trials on Hepatitis C Chronic in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations